Board summary
Key figures
47,634
Registered population
63.6% aged 18–64
14.0%
Aged 65+
ICB 19.0% · England 17.9%
8.2%
Ethnic minority (non-White)
3.5% Asian · England 9.6%
38.0%
In IMD quintile 1
ICB 31.9% · England 21.0%
~17,087
Core20 residents (est.)
Resident basis; registered basis ~18,161 · see page 3
6,430
Hypertension register
+5.55% in 3 yrs · England +5.60%
452
SMI register
11.4% of Cheshire East (LAD)'s
956
COPD register
Reviews +34.30% in 3 yrs
Forecast to 2030
7,395
Hypertension patients, 2030
+965 on today
79.9%
QRISK ≥20% on statins, 2030
+5.00pp over 3 yrs
3.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Smoking cessation support offers fell over three years.
Support offered fell 8.7 pp from 2023 to 2025 (England +0.1 pp) to 89.0% (England 94.2%), which may reflect review workflow gaps.
Under-eighty blood pressure control trails England.
Control in patients under 80 is 63.2% (England 67.8%) despite 89.4% having a recent reading, which could indicate treatment escalation gaps.
Lipid therapy in high-risk patients exceeds comparators.
Lipid-lowering therapy for QRISK ≥ 20% reaches 68.7% (England 63.6%; Cheshire East (LAD) 61.2%), rising +5.0 pp from 2023 to 2025 (England +3.8 pp).
Population, age and ethnicity
A younger population with 22.4% aged 0-17 contrasts with borough age patterns
Eagle Bridge PCN serves 47,634 registered patients across two practices. The PCN has a younger profile: 22.4% are aged 0-17, above Cheshire East (LAD) (18.3%), the ICB (19.2%) and England (19.6%), while 14.0% are aged 65+, below Cheshire East (22.6%), the ICB (19.0%) and England (17.9%). Based on Census usual residents rather than registered patients, the non-White ethnic minority share is 8.2%. Projected list growth of 2.8% to 2030 (Cheshire East 3.4%, ICB 2.3%, England 2.3%) rests on an unverified methodology.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 72.2% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 51.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 38.0% across the PCN and exceeds England at both practices
Across Eagle Bridge PCN, 38.0% of registered patients live in the Core20 cohort, compared with 9.2% in Cheshire East (LAD), 31.9% in the ICB and 21.0% in England. Both practices exceed England: Millcroft Medical Centre records 38.9% (12,013 estimated patients) and Earnswood Medical Centre records 36.7% (6,148 estimated patients). Across associated areas, 17,087 residents live in deciles 1 and 2, including 11,423 aged 18-64 and 3,954 aged 0-17. This widespread deprivation is consistent with network-wide outreach rather than single-practice targeting, prioritising working-age and family prevention.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
452
SMI register
0.91% recorded prevalence
209
Learning disability register
0.42% recorded prevalence
15
Care homes, 735 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
Recorded severe mental illness prevalence is 0.9% (452 patients), matching Cheshire East (0.9%) but below the ICB (1.1%) and England (1.0%). Learning disability prevalence is 0.4% (209 patients; Cheshire East 0.5%, ICB 0.6%, England 0.6%). Catchment care homes total 15 with 735 beds, though bed counts do not establish registered occupancy.
Severe mental illness: physical health checks
For severe mental illness, blood pressure checks were 79.4% (England 83.4%), BMI recording was 79.7% (England 82.1%), and alcohol checks were 79.4% (England 81.8%). These checks trail England, which audits could test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,430
Hypertension register
+5.55%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+1.81pp
BP control, under 80
≤140/90 · −1.38pp aged 80+
+965
More patients by 2030
Forecast 7,395 (14.43%)
Hypertension case-finding and control
The PCN records 6,430 hypertension patients (crude prevalence 12.9%; England 15.2%). Recent blood pressure checks reach 89.4% (Cheshire East (LAD) 88.4%; England 90.0%), with Earnswood Medical Centre at 92.5% and Millcroft Medical Centre at 87.5%. However, blood pressure control under 80 is 63.2%, trailing Cheshire East (LAD) (66.6%), the ICB (66.4%) and England (67.8%), with Millcroft Medical Centre at 61.2% and Earnswood Medical Centre at 66.8%. Control at age 80 and over is 81.5% (England 81.2%). Lower control under age 80 than England despite high recording could reflect medication titration gaps, which clinical audits could test.
Lipids and statins
Lipid-lowering therapy for QRISK ≥ 20% reaches 68.7%, above Cheshire East (LAD) (61.2%) and England (63.6%), led by Earnswood Medical Centre at 72.9% and Millcroft Medical Centre at 65.9%. Higher uptake than England shows strong primary prevention reach that the PCN should sustain across both practices.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 75,697 | £1.60 | £1.71 | £1.86 | £121,115 |
| Cardiovascular (all), 2025 | 100,514 | £3.27 | £4.37 | £3.33 | £328,681 |
In 2026, the PCN prescribed 75,697 lipid-modifying items at £1.60 per item (England £1.86; ICB £1.71), spending £19,681 less than England's unit cost. Spending less per item than England reflects unit-cost differences, though unit cost does not establish prescribing efficiency or clinical appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+21.79%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.45%
Asthma prevalence, PCN 3-yr % change
Recorded asthma prevalence is 5.6% (2,612 patients; England 6.6%), while COPD prevalence is 1.9% (956 patients; England 1.9%). Over three years, review rates rose: asthma reviews increased +21.8% to 63.3% (England +4.4% to 65.7%), and COPD reviews rose +34.3% to 74.2% (England +2.8% to 76.4%). Across practices, asthma reviews range from 58.4% at Earnswood Medical Centre to 66.1% at Millcroft Medical Centre, leaving an estimated 959 patients unreviewed. This shortfall highlights a sizeable recall opportunity to sustain review gains.
Cancer register and children's immunisation
The cancer register records 1,611 patients (3.2% prevalence; England 3.8%). In Q1 2025/26 childhood immunisations, 12-month 6-in-1 coverage reached 96.3% (England 91.0%), exceeding the 95.0% target. However, age-five coverage falls to 84.3% for MMR dose 2 (10.7 pp below the 95.0% target; 6.4 pp below dose 1) and 81.4% for the 4-in-1 booster (13.6 pp below target). Lower age-five uptake could reflect recall gaps, which practice-level audits could test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) and 19.5 pp below the national ambition of 75.0% by 2028. Known-stage share was 72.8% (13,490 of 18,522 registered cancers), and early-stage share rose +2.6 pp from 2013 to 2022. Locally, PCN breast screening coverage is 63.3%, below Cheshire East (LAD) (74.5%) and England (69.9%). Cervical screening in women aged 25-49 is 66.7%, trailing Cheshire East (LAD) (73.6%). These system staging figures describe the wider ICB, not PCN performance. Lower screening uptake may delay early-stage case ascertainment across primary care.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Mid Cheshire Hospitals NHS Foundation Trust in Jul 2026 (provisional), the 62-day referral to treatment standard achieved 71.1% (130.5 of 183.5 pathways), 13.9 pp below the 85.0% standard, trailing NHS Cheshire and Merseyside Integrated Care Board (76.2%) and close to England (71.2%). The 28-day faster diagnosis standard reached 80.0% (1,743 of 2,180), exceeding the 75.0% standard. The 31-day combined treatment standard was 86.2% (125 of 145), below the 96.0% standard. For diagnostic tests, 12.7% waited 6+ weeks. These trust figures describe provider performance, not PCN performance.
| Pathways within standard (%) | Mid Cheshire | of North Midlands | East Cheshire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 79.95 | 80.65 | 81.08 | 77.25 | 79.32 |
| 31-day treatment (96%) | 86.21 | 93.85 | 96.30 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 71.12 | 68.84 | 53.41 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mid Cheshire | of North Midlands | East Cheshire | England |
|---|---|---|---|---|
| MRI | 5.15 | 36.13 | 26.62 | 21.40 |
| CT | 1.09 | 2.86 | 11.49 | 9.92 |
| Echocardiography | 5.51 | 45.39 | 26.24 | 28.48 |
| Colonoscopy | 30.34 | 46.53 | 10.85 | 30.83 |
| Gastroscopy | 31.89 | 15.49 | 10.25 | 29.02 |
| All 15 DM01 tests | 12.72 | 22.94 | 16.17 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). For Cheshire East residents in Jun 2026 (provisional), experimental community data recorded 135,460 care activities, 72,825 care contacts, 21,910 patients with a contact, and 18,280 referrals. Adults aged 65+ accounted for 60.8% of contacts. These figures reflect submitting providers for borough residents, not unique PCN patients.
Practice variation and patient experience
Immunisation achievement diverges by 29.3 pp while phone access trails England across both practices
Clinical QOF achievement reached 100.0% at Millcroft Medical Centre and 98.4% at Earnswood Medical Centre (England 97.1%). In contrast, vaccination and immunisation achievement diverges by 29.3 pp, from 48.5% at Earnswood Medical Centre to 19.1% at Millcroft Medical Centre (England 55.2%). This divergence could reflect recording or recall differences, which practice-level audits could test.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Earnswood | 98 | 36.7 | 27.4% | 72.0% | 73.1% |
| Millcroft | 101 | 38.9 | 30.6% | 78.2% | 65.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Smoking cessation support fell 8.7 pp while heart failure reviews rose 137.2%
The PCN achieved substantial three-year review gains in heart failure (+137.2% versus England +8.7%), COPD (+34.3% versus +2.8%), and asthma (+21.8% versus +4.4%). However, smoking cessation support for at-risk patients fell 8.7 pp to 89.0% (England +0.1 pp to 94.2%; Cheshire East (LAD) -2.1 pp to 94.4%). Diabetes HbA1c control without frailty fell 0.2% over three years to 51.6% (England +4.4% to 57.4%). These diverging trajectories could reflect uneven routine follow-up, which clinical pathway audits could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Smoking support (SMI)
Diabetes HbA1c control
BP control, 80+
Stroke register
BP control, under 80
Heart failure reviews
COPD reviews
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 15 (735 beds) | n/a | Schools (catchment) | 71 | n/a |
| Children's centres | 3 | 14 | Places of worship | 31 | 272 |
| Libraries | 1 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 7 | 41 | Primary academies | 12 | 78 |
| Special schools | 2 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Asthma annual review recall clinic
Asthma review coverage is 63.3% (Cheshire East (LAD) 64.5%; England 65.7%), leaving an estimated 959 of 2,612 patients unreviewed. For discussion, practices could run template-driven asthma review recall and offer flexible after-school or weekend slots across both practices. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Smoking cessation support pathway audit
Smoking cessation support offered to patients with certain conditions is 89.0% (Cheshire East (LAD) 94.4%; ICB 95.2%; England 94.2%) after falling 8.7 pp over 2023 to 2025 (England +0.1 pp). Low cost, quick to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Under-eighty hypertension titration review
Blood pressure control under age 80 is 63.2% (Cheshire East (LAD) 66.6%; ICB 66.4%; England 67.8%), with Millcroft Medical Centre at 61.2% and Earnswood Medical Centre at 66.8%. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Network Core twenty outreach model (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster catch up (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening uptake recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Asthma annual review recall clinic (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Smoking cessation support pathway audit (p12) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | MHIS · From Harm to Hope · Core20PLUS5 · 10YHP equity test | PCN & Practice |
| Option 3 · Under-eighty hypertension titration review (p12) | Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
